Blog

Quick Facts About AbituzumabWhat is Abituzumab?Abituzumab is a monoclonal antibody that targets αv-integrins, playing a role in cancer treatment and fibrotic diseases.What is the mechanism of action for Abituzumab?It inhibits αv-integrins to prevent tumor cell adhesion, migration, and survival, making it a potential therapy for colorectal and prostate cancer.What are the clinical applications of Abituzumab?It has been investigated for metastatic colorectal cancer (CRC), prostate cancer, systemic sclerosis, and fibrotic diseases like scleroderma.1.) Understanding AbituzumabInitially developed by Merck Serono, Abituzumab has undergone extensive preclinical and clinical evaluation …

Quick Facts About ApamistamabWhat is Apamistamab?Apamistamab is a monoclonal antibody that targets the CD45 antigen on hematopoietic cells.How does Apamistamab work?When labeled with the radioactive isotope Iodine-131, Apamistamab delivers targeted radiation to CD45-expressing cells, aiding in the eradication of malignant cells.What are the clinical applications of Apamistamab?Apamistamab is primarily used in conditioning regimens before hematopoietic cell transplantation for patients with relapsed or refractory acute myeloid leukemia (AML).1.) Understanding ApamistamabApamistamab, also known as Iomab-B when conjugated with Iodine-131, is an innovative therapeutic agent designe …

Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate immune response in lupus.What is the mechanism of action of Litifilimab?Litifilimab inhibits BDCA2, reducing inflammatory cytokine production and modulating the immune system, potentially benefiting lupus patients.What are the clinical applications of Litifilimab?Litifilimab is being investigated for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), with Phase 3 trials ongoing.1.) Understanding LitifilimabDeveloped by Biogen, Litifilimab has shown promising results in e …